Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by significant cognitive and behavioral impairments. Near-infrared (NIR) light treatment has shown potential in cognitive improvement in previous studies. However, clinical trials of NIR for AD remain limited.
Objective
This study investigated the safety and effects of whole-head 810 nm NIR therapy in AD patients, including long-term efficacy.
Methods
An open-label pilot study on whole-head NIR treatment for AD patients was conducted. Nine AD patients completed 4-month treatment (810 nm, 100 mW/cm², 30 min/session, 6 sessions weekly). Safety and efficacy were evaluated at baseline, months 2 and 4, and 2-month post-treatment.
Results
After four months of whole-head NIR treatment, mean changes from baseline on the Mini-Mental State Examination were 3.2 (p = 0.02). Mean changes from baseline on the Alzheimer's Disease Assessment Scale-Cognitive were −5.0 (p = 0.05), mean changes from baseline on the Montreal Cognitive Assessment were 1.9 (p = 0.12). Mean changes from baseline on the Neuropsychiatric Inventory were −4.2 (p = 0.47). These benefits were sustained two months at least. With no device-related adverse effects were reported.
Conclusions
Whole-head 810 nm NIR light is safe and offers promising benefits for AD patients. To fully confirm its efficacy, durability, and underlying mechanisms, further large-scale randomized controlled trials are necessary.
PrinceMJWuFGuoY, et al.The burden of disease in older people and implications for health policy and practice. Lancet2015; 385: 549–562.
2.
NandiACountsNChenS, et al.Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: a value of statistical life approach. EClin Med2022; 51: 101580.
3.
Pardo-MorenoTGonzález-AcedoARivas-DomínguezA, et al.Therapeutic approach to Alzheimer’s disease: current treatments and new perspectives. Pharmaceutics2022; 14: 1117.
4.
CummingsJLTongGBallardC. Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J Alzheimers Dis2019; 67: 779–794.
5.
AilioaieLMAilioaieCLitscherG. Photobiomodulation in Alzheimer’s disease—A complementary method to state-of-the-art pharmaceutical formulations and nanomedicine?Pharmaceutics2023; 15: 916.
6.
MosilhyEAAlshialEEEltarasMM, et al.Non-invasive transcranial brain modulation for neurological disorders treatment: a narrative review. Life Sci2022; 307: 120869.
7.
LuYWangRDongY, et al.Low-level laser therapy for beta amyloid toxicity in rat hippocampus. Neurobiol Aging2017; 49: 165–182.
8.
NizamutdinovDEzeuduCWuE, et al.Transcranial near-infrared light in treatment of neurodegenerative diseases. Front Pharmacol2022; 13: 965788.
9.
SalehpourFHamblinMR. Photobiomodulation for Parkinson’s disease in animal models: a systematic review. Biomolecules2020; 10: 610.
10.
DennisELThompsonPM. Functional brain connectivity using fMRI in aging and Alzheimer’s disease. Neuropsychol Rev2014; 24: 49–62.
11.
SaltmarcheAENaeserMAHoKF, et al.Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation. Case series report. Photomed Laser Surg2017; 35: 432–441.
12.
ChaoLL. Effects of home photobiomodulation treatments on cognitive and behavioral function, cerebral perfusion, and resting-state functional connectivity in patients with dementia: a pilot trial. Photobiomodul Photomed Laser Surg2019; 37: 133–141.
13.
BraakHBraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
14.
Plascencia-VillaGPerryG. Neuropathologic changes provide insights into key mechanisms of Alzheimer disease and related dementia. Am J Pathol2022; 192: 1340–1346.
15.
YuanYCassanoPPiasM, et al.Transcranial photobiomodulation with near-infrared light from childhood to elderliness: simulation of dosimetry. Neurophotonics2020; 7: 015009.
16.
CassanoPTranAPKatnaniH, et al.Selective photobiomodulation for emotion regulation: model-based dosimetry study. Neurophotonics2019; 6: 015004.
17.
NizamutdinovDQiXBermanMH, et al.Transcranial near infrared light stimulations improve cognition in patients with dementia. Aging Dis2021; 12: 954.
18.
SalehpourFHamblinMRDiduroJO. Rapid reversal of cognitive decline, olfactory dysfunction, and quality of life using multi-modality photobiomodulation therapy: case report. Photobiomodul Photomed Laser Surg2019; 37: 159–167.
19.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 263–269.
20.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 270–279.
21.
KatzmanRZhangMWangZ, et al.A Chinese version of the mini-mental state examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol1988; 41: 971–978.
22.
ChenKLXuYChuAQ, et al.Validation of the Chinese version of Montreal cognitive assessment basic for screening mild cognitive impairment. J Am Geriatr Soc2016; 64: e285–e290.
23.
RaghavanNSamtaniMNFarnumM, et al.The ADAS-cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement2013; 9: S21–S31.
24.
MegaMSCummingsJLFiorelloT, et al.The spectrum of behavioral changes in Alzheimer’s disease. Neurology1996; 46: 130–135.
25.
MahoneyFIBarthelDW. Functional evaluation: the Barthel Index: a simple index of independence useful in scoring improvement in the rehabilitation of the chronically ill. Md State Med J1965; 14: 61–65.
26.
BermanMHHalperJPNicholsTW, et al.Photobiomodulation with near infrared light helmet in a pilot, placebo controlled clinical trial in dementia patients testing memory and cognition. J Neurol Neurosci2017; 8: 176.
27.
HanLColeMBellavanceF, et al.Tracking cognitive decline in Alzheimer’s, disease using the Mini-mental state examination: a meta-analysis. Int Psychogeriatr2000; 12: 231–247.
28.
SalmonDPThalLJButtersN, et al.Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology1990; 40: 1225–1225.
29.
MendiondoMSAshfordJWKryscioRJ, et al.Modelling mini mental state examination changes in Alzheimer’s disease. Stat Med2000; 19: 1607–1616.
30.
WinbladBEngedalKSoininenH, et al.A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology2001; 57: 489–495.
31.
SternRGMohsRCDavidsonM, et al.A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatr1994; 151: 390–396.
32.
YesavageJAPoulsenSLSheikhJ, et al.Rates of change of common measures of impairment in senile dementia of the Alzheimer’s type. Psychopharmacol Bull1988; 24: 531–534.
33.
JiaJJiYFengT, et al.Sixteen-week interventional study to evaluate the clinical effects and safety of rivastigmine capsules in Chinese patients with Alzheimer’s disease. J Alzheimers Dis2019; 72: 1313–1322.
34.
PruittTWangXWuA, et al.Transcranial photobiomodulation (tPBM) with 1,064-nm laser to improve cerebral metabolism of the human brain in vivo. Lasers Surg Med2020; 52: 807–813.
35.
GhaderiAHJahanAAkramiF, et al.Transcranial photobiomodulation changes topology, synchronizability, and complexity of resting state brain networks. J Neural Eng2021; 18: 046048.
36.
DmochowskiGMShereenADBerishaD, et al.Near-infrared light increases functional connectivity with a non-thermal mechanism. Cereb Cortex Commun2020; 1: tgaa004.
37.
MeinzerMLindenbergRAntonenkoD, et al.Anodal transcranial direct current stimulation temporarily reverses age-associated cognitive decline and functional brain activity changes. J Neurosci2013; 33: 12470–12478.
38.
QuXLiLZhouX, et al.Repeated transcranial photobiomodulation improves working memory of healthy older adults: behavioral outcomes of poststimulation including a three-week follow-up. Neurophotonics2022; 9: 035005.
39.
KheradmandADonboliSTanjaniPT, et al.Therapeutic effects of low-level laser therapy on cognitive symptoms of patients with dementia: a double-blinded randomized clinical trial. Photobiomodul Photomed Laser Surg2022; 40: 632–638.
40.
BonavitaSSaccoRDella CorteM, et al.Computer-aided cognitive rehabilitation improves cognitive performances and induces brain functional connectivity changes in relapsing remitting multiple sclerosis patients: an exploratory study. J Neurol2015; 262: 91–100.
